Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RAPP 
Rapport Therapeutics, Inc. Common Stock (RAPP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/10/2025: RAPP (1-star) is a SELL. SELL since 1 days. Simulated Profits (48.33%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $52.14
1 Year Target Price $52.14
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.19% | Avg. Invested days 28 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.22B USD | Price to earnings Ratio - | 1Y Target Price 52.14 |
Price to earnings Ratio - | 1Y Target Price 52.14 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 6.43 - 42.27 | Updated Date 11/10/2025 |
52 Weeks Range 6.43 - 42.27 | Updated Date 11/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.27 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.732 | Actual -0.71 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -15.89% | Return on Equity (TTM) -23.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1067489724 | Price to Sales(TTM) - |
Enterprise Value 1067489724 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 47661138 | Shares Floating 30079897 |
Shares Outstanding 47661138 | Shares Floating 30079897 | ||
Percent Insiders 4.71 | Percent Institutions 90.12 |
Upturn AI SWOT
Rapport Therapeutics, Inc. Common Stock
Company Overview
History and Background
Rapport Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision medicines for central nervous system (CNS) disorders. Founded in 2022, Rapport is working to advance precision therapeutics by leveraging the insights gained from the identification and understanding of genetic drivers of neurological disorders. They target specific receptor-associated proteins.
Core Business Areas
- Discovery and Development of CNS Therapeutics: Rapport Therapeutics focuses on the discovery and development of precision medicines targeting genetically defined neurological conditions. Their strategy involves identifying and validating receptor-associated proteins as drug targets.
- Preclinical and Clinical Programs: Rapport Therapeutics is working to build a robust pipeline of preclinical and clinical programs focused on addressing unmet needs in neurological disorders. Their lead programs target specific receptor associated proteins with the goal of improved efficacy and reduced side effects compared to current treatments.
Leadership and Structure
Rapport Therapeutics has a management team with experience in drug discovery and development. The organizational structure appears to be based around research and development, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- RAP-219: RAP-219 is Rapport Therapeutics' lead clinical program, targeting pain. It is a selective and potent inhibitor designed to modulate the activity of genetically validated pain targets. As a Phase 1 trial is underway, there is no current revenue, market share, or number of users. Competitors: Existing pain medications (opioids, NSAIDs, etc.) and other companies developing novel pain therapies.
Market Dynamics
Industry Overview
The CNS therapeutics market is large and growing, with significant unmet needs in many neurological disorders. Factors driving growth include an aging population, increasing prevalence of neurological conditions, and advances in drug discovery and development.
Positioning
Rapport Therapeutics positions itself as a leader in precision CNS therapeutics, leveraging genetics to develop targeted therapies. Its competitive advantage lies in its focus on genetically defined patient populations and its ability to design drugs that selectively modulate the activity of disease-causing proteins.
Total Addressable Market (TAM)
The TAM for CNS therapeutics is estimated to be significant, potentially in the hundreds of billions of dollars. Rapport Therapeutics is positioned to capture a share of this market by focusing on specific, genetically defined patient populations with high unmet needs.
Upturn SWOT Analysis
Strengths
- Strong scientific team
- Focus on precision medicine
- Novel drug targets
- Proprietary technology platform
Weaknesses
- Early stage company
- Limited clinical data
- Dependence on key personnel
- High cash burn rate
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new indications
- Advancement of clinical programs
- Regulatory approvals
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- BIOX
- ALNY
- VIR
Competitive Landscape
Rapport Therapeutics competes with other biotechnology companies developing CNS therapeutics. Its focus on precision medicine and genetically defined patient populations could provide a competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's recent founding. Growth is focused on advancing preclinical and clinical programs.
Future Projections: Future growth depends on clinical trial success, regulatory approvals, and commercialization of its products. Analyst estimates are unavailable due to limited coverage.
Recent Initiatives: Recent initiatives include advancing the RAP-219 clinical program and expanding the pipeline through drug discovery efforts.
Summary
Rapport Therapeutics is an early-stage biotech company focused on precision CNS therapies, offering both potential and risk. Its strategic focus and strong scientific team represent key strengths, however its reliance on financing and clinical trial success pose significant challenges. The company needs to successfully advance its clinical programs and secure additional funding, and they must be aware of the competitive landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Press Releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made with careful consideration of all available information and risk factors.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rapport Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2024-06-07 | CEO, President, Treasurer & Director Mr. Abraham N. Ceesay M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 69 | Website https://www.rapportrx.com |
Full time employees 69 | Website https://www.rapportrx.com | ||
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.